# A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

> **NCT06240728** · PHASE1 · RECRUITING · sponsor: **NextPoint Therapeutics, Inc.** · enrollment: 144 (estimated)

## Conditions studied

- Metastatic Malignant Neoplasm

## Interventions

- **DRUG:** NPX887

## Key facts

- **NCT ID:** NCT06240728
- **Lead sponsor:** NextPoint Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06240728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06240728, "A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06240728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*